The opioid crisis is now a national "Public Health Emergency" - and this one company could help end it...

Please do not reply to this message, as replies are routed to an unmonitored mailbox. You are receiving this email as a part of your subscription to Strategic Tech Investor. Your ability to alter your subscription information can be found at the bottom of this email. [Strategic Tech Investor] [You wanted something better from us (well, here it is)]( We've gotten your letters... We've heard your complaints, loud and clear. You want something BIGGER from us... Something that could make you SUPERIOR returns... in just DAYS... A service that is better and bolder than any initiative we've undertaken so far... Well, here it is... [Watch this]( and you'll thank me later. --------------------------------------------------------------- November 3, 2017 [The Opioid Crisis Is Now a National "Public Health Emergency" - and This One Company Could Help End It]( By Michael A. Robinson Dear Strategic Tech Investor Reader, LATEST REPORT --------------------------------------------------------------- [As the Market Hits Another Top, Here's What Drives Me Nuts]( While it sounds counterintuitive, many investors stay out of record markets like the one we're seeing now because they fear the good times could come to an end at any moment. I know this describes many of you folks because you write and tell me that you're afraid of this "peaky" market. Fear no longer. If you've got the right "toolkit," you can stay in any sort of market - a high one poised for a dip, a low one about to soar, or anything in between - and make money. A lot of money. [Here's what you need...]( LATEST APPEARANCE --------------------------------------------------------------- ["This Is Not Your Grandfather's..."]( MICHAEL'S LATEST ALERTS --------------------------------------------------------------- Research [This Big Alcohol Company Just Revealed the Future of Legal Marijuana]( Trading [Your Shares Soar 25% in One Day - and Your Bonus Calls Double]( Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it's easy to forget where we got started here. Legal marijuana first came to my attention because of the "War on Pain." Let me explain... In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country's pain sufferers may run as high as 50 million. But I don't need statistics to know that millions of Americans suffer from serious pain problems. I do so myself - and so do many of my friends and family members. And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now. Other studies say it's even bigger. Equally huge is the nation's opioid crisis. President Donald Trump has declared the opioid crisis a "public health emergency," and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment. The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day. This surge in the number of pain sufferers - coupled with the snapback against the prescription of opioid drugs - has opened the door to a wholly new approach to pain treatment. I'm talking about medical marijuana and all its derivatives. And there's one company, in particular, that you should be watching... --------------------------------------------------------------- [PROFIT OPPORTUNITY]( The company I'm telling you about in today's report has already delivered peak gains of more than 65% to folks who got in early with my [Roadmap to Marijuana Millions](. That's the incredibly diversified list of more than 30 of the best legal marijuana stocks on the market that comes free with a subscription to my Nova-X Report investing research service. But that 65% is small potatoes compared to some of the wins those Nova-X members have made. They're currently sitting on gains of 488%... 327%... 229%... and at least six other triple-digit gainers. Along the way, some of these picks have reached quadruple-digit peak gains. And that's in just a little over a year! Thanks to recreational cannabis going legal in California and Canada next year - and many more states lining up to legalize - there's much more to come. This market could be worth $20 billion or more by 2020, and my ["weed investors' bible"]( can show you how to potentially get your share. To get it, [just go here now...]( --------------------------------------------------------------- Why We Believe in Medical Marijuana In fact, marijuana's medicinal potential could be worth billions more than the recreational market. Study after study has shown that up to two dozen medical conditions could be treated with marijuana. Two of its more intriguing components, non-psychoactive cannabidiol (CBD) and psychoactive tetrahydrocannabinol (THC), have a clear impact on brain function and pain management. Glaucoma sufferers, for example, have long known that pot can reduce ocular swelling. Many people swear by pot's ability to improve lung function, counterintuitive as that may seem. And people suffering from conditions such as multiple sclerosis will tell you that this drug can greatly ease the daily pain they must live with. --------------------------------------------------------------- [What the Latest Amazon Cryptocurrency News Really Means for Investors]( Earlier this week, Amazon.com Inc. registered three cryptocurrency domain names: AmazonEthereum.com, AmazonCryptocurrency.com, and AmazonCryptocurrencies.com. No, Amazon isn't going to start accepting Bitcoin tomorrow. But the online retail giant has developed its own virtual currency, and the registration of the domain names suggests that it's more than wishful thinking that Amazon could accept crypto payments in the future. Still, the excitement is premature. [Here's what Amazon's new websites really mean for cryptocurrencies...]( --------------------------------------------------------------- In fact, some of my friends can tell you that. Results like those are part of the reason medical marijuana has been approved in 29 states (and Washington, D.C.) and in many countries around the world. And it's the reason why the global medical marijuana market topped $11 billion in 2016 - and could reach $55.8 billion by 2025. And it's what brought medical marijuana - and all the biotechnology behind it - to my attention. Just one company - a biotech that first hit my radar in 2014 and has delivered peak gains of more than 65% to folks who got in early with my [Roadmap to Marijuana Millions]( - is favorably positioned to make a classic "corner-the-market" move on this incredibly lucrative segment. I'm recommending it once more today, because I think there's every reason for it to keep on delivering... This Company Will Dominate All this got the scientists at the Cambridge, U.K.-based GW Pharmaceuticals Plc (Nasdaq ADR: [GWPH]() thinking: If marijuana has such a broad range of potentially healing properties, and is finally receiving more respect among doctors, why not build a business around CBD and THC? GW has an unbeatable head start in the race to build drug franchises around the healing powers of cannabis. You see, all the way back in 1998 - the Dark Ages, in terms of legal cannabis - this company successfully lobbied the U.K. government for the country's first-ever "cultivation license" to grow cannabis for commercial, scientific research. --------------------------------------------------------------- [Shipping 500 Free Books Today [Claim Yours]]( With the secrets you'll find in this book, I've produced 89 chances to double, triple, and even quadruple your money in the past two and a half years - 42 chances this year alone! Fun fact: You only have to double $500 eleven times to turn it into $1 million. [Click here]( to learn how you can claim your free copy today. --------------------------------------------------------------- For the past five years, GW has been cultivating strains of the plant with an eye to increasing concentrations of these two key ingredients. This effort has made it possible for GW to provide its engineers with a robust supply of the raw material they need as they ramp up research into a broad range of new drug candidates. GW's scientists are looking to capitalize on a series of medical breakthroughs made in the 1990s, when researchers first realized that the body actually has three systems that regulate disease and pain. Two of these, the central nervous system and the immune system, were already well understood. But what researchers discovered was that our body is also regulated by proteins called endocannabinoid receptors. THC and CBD go right to these receptors and can have a profound impact on the body's various mental and physical responses. GW Pharma has focused on the impact of CBD, which targets the brain's receptors that control mood and brain seizures. Its research has been fruitful, showing incredible promise. A "Miraculous" Treatment For the 3 million epilepsy sufferers in the United States (and the 62 million sufferers worldwide), relief from debilitating seizures would be nothing short of a miracle. That's why so many of them are focused on GW's Epidiolex, which has been quickly moving through clinical trials. A turning point came in 2012, when an 11-year-old boy named Sam was given high doses of CBD for the first time. You see, despite having taken a dozen anti-seizure medications, Sam still suffered from more than 100 seizures every day. Thanks to GW Pharma's CBD formulation, Sam now experiences only three to five seizures each day. Some days, he doesn't have a single one. As you'd imagine, many families are clamoring to get their children enrolled in Epidiolex clinical trials. They soon got their wish. By 2015, 20 separate studies were underway involving 750 children. On average, patients have experienced a greater than 50% reduction in seizures. Fully 95% of all patients enrolled in clinical trials for this drug have stayed in the program. That's very significant, because, typically, a combination of toxic side effects and lack of effectiveness leads 20% or more of patients to drop out of trials like this. But Epidiolex has shown only fatigue (in 17% of patients), diarrhea (17%), and sleepiness (21%) as side effects. --------------------------------------------------------------- IPO NEWS: [Don't Wait for the Ginkgo Bioworks IPO to Profit From This $3 Billion Industry]( Some investors are targeting the Ginkgo Bioworks IPO as their next big profit opportunity. The biotech firm programs cells to produce the enzymes needed to make cheese and yogurt. Gingko also makes microbes that generate rose oil for the French fragrance firm Robertet Group. But you're going to have to wait to get a piece of Ginkgo stock. It hasn't announced plans for a public offering. [That's why, today, we want to share a profit opportunity happening right now in the $3 trillion healthcare industry...]( --------------------------------------------------------------- Based on these results, GW Pharmaceuticals has a head start on all of its competitors. In fact, Epidolex's U.S. trials are already wrapped up, and GW plans to file for U.S. Food and Drug Administration approval soon. And that means Epidiolex could launch early next year. Following approval, GW Pharma will have exclusive sales rights to the drug for seven years in the United States and 10 years in Europe. Those will be very profitable years. Right now, GW Pharma is looking to make its treatments available to 466,000 children in the United States who suffer from epilepsy and another 208,000 in key European markets. These patients currently consume tens of thousands of dollars in epilepsy medicine each year, drugs that barely make a dent in the number of daily seizures they must endure. GW is also testing Epidiolex in Phase II trials with adult epilepsy patients. That's a far larger market, as there are around 65-million adults with epilepsy worldwide. Simply put, sales for juveniles alone could be a blockbuster drug launch. Solely based on approval for children with epilepsy, annual sales for Epidiolex may exceed $1 billion five years from now - "official" blockbuster status. Don't expect the pot pioneers at GW to stop at Epidiolex, either. On the Fast Track Even as GW prepares to tackle the epilepsy market, its scientists have been testing high concentrations of CBD on patients with: - schizophrenia, - type 2 diabetes; - perinatal asphyxia; - and other types of seizure. Another non-psychoactive compound, a homolog of CBD known as cannabidivarin (CBDV), is also showing a lot of promise in other areas, including treating certain social and repetition behaviors associated with autism. In April 2014, the company received the coveted FDA "Fast Track" designation for Sativex for "the treatment of pain in patients with advanced cancer." The drug has already been launched in 30 other countries for the treatment of spasticity caused by multiple sclerosis. The FDA's Fast Track program grants a drug maker favorable treatment for the purpose of accelerating the development of a drug that both treats a deadly condition and also addresses an unmet medical need. Ahead of its first drug hitting the U.S. market, GW Pharma is already building the foundation to become a top-tier drug maker. --------------------------------------------------------------- [Great News for Folks Who Want to Help "Make America Great Again"]( Behind the scenes, the Pentagon is secretly placing big bets on a mind-blowing new technology designed to put America on top for decades. It's being developed by a tiny defense company selling for just $6 a share. But that could change FAST. In fact, this firm's new, top-secret technology could be on the verge of creating $45 billion in new wealth for American patriots who act right now. [Frankly, you need to see this before it's too late](. --------------------------------------------------------------- For instance, Julian Gangolli is president of its North America division. Gangolli earlier ran the North American sales operations for Allergan PLC (NYSE: [AGN](), a $97 billion drug and medical supplier. Plus, GW has already identified the 4,000 to 5,000 U.S. physicians that specialize in epilepsy - and has sales reps lined up ready to hit them. This firm is well armed to pursue an active slate of drug trials and the buildout of a sales force. It has around $372.1 million in cash in the bank, as of the end of the second quarter of 2017. The success in treating epilepsy will change how the marijuana-based drugs are perceived. We're incredibly close now, and once the medical community sees how compounds such as CBD, CBDV, and THC deliver much better results than existing treatments, GW Pharma and other cannabis-focused stocks will be no longer be seen as outliers; they'll be must-own stocks, and essential earners in savvy investors' portfolios. Now, I've just released my updated [Roadmap to Marijuana Millions: Phase II](. That's an incredibly diversified list of more than 30 of the best legal marijuana stocks on the market. This market could be worth $20 billion or more by 2020, and my ["weed investors' bible"]( can show you how to potentially get your share. It's free with a subscription to my Nova-X Report investing research service. [Click here to learn more...]( Have a great weekend. I'll see you back here next week. Follow me on [Facebook]( and [Twitter](. Here's what else I'm following... --------------------------------------------------------------- [BREAKING: New Legislation Could Turn Tiny Pot Stocks into Millions]( Thanks to just announced, historic legislation, a new pot stock boom is about to blow the doors off anything we've seen up to this point. In a time sensitive [audio briefing](, I detail five pot stocks that are best positioned to skyrocket upon legalization and how you can grab your stake in them. [Click here to listen to the briefing](. Then take notes... these penny stocks could make you a fortune. [This One Tiny Number Can Double Your Money]( There are billions and billions of dollars up for grabs out there thanks to global corporations and other huge enterprises moving their IT services to the cloud. That gives tech investors a target-rich environment. So let's look what I think will be a hugely profitable way to invest in this massive market. It's a company the mainstream financial media virtually ignores. [And it's going to double your money in two years...]( You Won't Guess Who Just Saved America's Biofuels Solar and wind may get all the headlines, but biofuels are a crucial renewable energy source. Unlike the rest, biofuels can be used right now as liquid fuel in today's vehicles. That makes biofuels a crucial source of energy - and as Global Energy Strategist Dr. Kent Moors explains, a political hot potato. While oil rich states don't want the competition from biofuels, farming states where the crops that get turned into biofuel are grown want as much of it as possible. Well, this fight is coming to an end, and it looks like biofuels have won - with some unexpected help. To see how energy markets will react, what this means for your wallet, and to get all of Kent's Oil & Energy Investor research free of charge, just [click here](. [They've Got the Tech Marijuana Firms Need to Grow the "Good Stuff"]( They may call it "weed," but commercial legal cannabis - the "good stuff" - is more like a pampered, pedigreed dog. A lot of care, technique, and technology goes into the cultivation and feeding of marijuana plants. All that's needed so those plants can flower and produce commercially and medically useful compounds. This is labor- and tech-intensive stuff. It's also the specialty of this company. [With it, you can tap the profit power in legal cannabis and keep your risk low...]( YOU MAY HAVE MISSED... --------------------------------------------------------------- [BREAKING: These Investors Are Making 44% Gains... Every Day]( [Google's Real "Next Big Thing"]( [Shipping 500 Free Books Today [Claim Yours]]( [This Bitcoin Price Prediction Chart Is a Trader's Dream]( [The Pentagon Has Begun a Massive "Pacific Pivot"]( --------------------------------------------------------------- [Facebook]( [Twitter]( [More...]( mailto:?subject=Michael%20Robinson's%20Strategic%20Tech%20Investor&body=Check%20out%20http%3A%2F%2Fwww.strategictechinvestor.com%2F You are receiving this e-mail at, {EMAIL}, as a part of your free subscription to Strategic Tech Investor. Remove your email from this list: [Unsubscribe]( To cancel by mail or for any other subscription issues, write us at: Strategic Tech Investor | Attn: Member Services | 16 West Madison Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 [Contact Customer Service]( Website: []( © 2017 Strategic Tech Investor All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Strategic Tech Investor. 16 West Madison Street, Baltimore MD 21201.